Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Inflammation-induced bone loss: can it be prevented?

Evange Romas1, Matthew T Gillespie

  • 1The University of Melbourne, St. Vincent's Hospital, 41 Victoria Parade, Fitzroy, 3065, Australia. romase@svhm.org.au

Rheumatic Diseases Clinics of North America
|February 10, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Eculizumab therapy and complement regulation in a case of resistant catastrophic antiphospholipid syndrome.

BMJ case reports·2024
Same author

Abdominal vagus nerve stimulation alleviates collagen-induced arthritis in rats.

Frontiers in neuroscience·2022
Same author

Paraneoplastic systemic lupus erythematosus associated with colorectal cancer.

Oxford medical case reports·2019
Same author

Melphalan modifies the bone microenvironment by enhancing osteoclast formation.

Oncotarget·2017
Same author

Urolithiasis is prevalent and associated with reduced bone mineral density in β-thalassaemia major.

Internal medicine journal·2017
Same author

Perceptions of Doppler ultrasound for rheumatoid arthritis disease activity assessment and education.

International journal of rheumatic diseases·2017

Osteoclast (OCL) inhibition effectively prevents inflammatory bone loss in rheumatoid arthritis (RA). Emerging therapies targeting RANKL and other pathways offer new strategies for bone protection, complementing existing treatments.

Area of Science:

  • Rheumatology and Immunology
  • Bone Biology and Pathophysiology
  • Pharmacology and Therapeutics

Background:

  • Inflammatory synovitis in rheumatoid arthritis (RA) leads to significant bone loss, primarily mediated by osteoclast (OCL) activity.
  • While anti-TNF therapies are established for preventing bone loss, patient response varies, and side effects limit long-term use.
  • Alternative treatments like rituximab and abatacept are emerging for anti-TNF-resistant RA patients.

Purpose of the Study:

  • To review emerging therapeutic strategies for preventing inflammation-induced bone loss in RA.
  • To discuss the role of targeting osteoclastogenesis, particularly RANKL inhibition, in managing RA-associated bone destruction.
  • To evaluate the potential of novel agents, including bisphosphonates and PTH, in conjunction with OCL inhibition.

Related Experiment Videos

Main Methods:

  • Review of current literature on inflammatory bone loss in RA and therapeutic interventions.
  • Analysis of proof-of-concept studies and clinical trials for emerging treatments targeting OCLs and RANKL.
  • Discussion of the clinical application and limitations of various bone-protective strategies.

Main Results:

  • Targeting RANK-mediated osteoclastogenesis shows promise in preventing inflammatory bone loss, with Denosumab demonstrating efficacy.
  • RANKL inhibition is a potential treatment of choice for RA bone loss but does not address synovitis, necessitating combination therapy (e.g., with MTX).
  • Newer bisphosphonates (BPs) and pulsed parathyroid hormone (PTH) show potential for bone protection, though long-term safety and clinical efficacy require further investigation.

Conclusions:

  • Strategies normalizing osteoclast numbers are crucial for effective prevention of inflammation-induced bone loss in RA.
  • RANKL antagonism offers a targeted approach for bone protection but requires integration with synovitis treatments.
  • Further research is needed to confirm the long-term safety and clinical utility of novel bone-protective agents in RA management.